公开(公告)号：EP0759815B1

公开(公告)日：2002-10-30

申请号：EP95918992.9

申请日：1995-05-05

申请人： Merck & Co., Inc.

发明人： ARCHER, John, R. ,  CUMPSTEY, David, E. ,  GRAY, Richard, H. ,  OWEN, Stephen

IPC分类号： B07C5/342 ,  B07C5/38 ,  B65B5/10 ,  B65B57/14

CPC分类号： G01N21/9508 ,  B07C5/342 ,  B07C5/38 ,  B65B5/103 ,  B65B57/14 ,  Y10S209/92

摘要： A system and method for automatically feeding, inspecting and diverting tablets for continuous filling of tablet containers includes a tablet conveyor system (1) which divides the tablets in a plurality of streams for inspection by color, size and shape. Following the tablet inspection, each tablet passes through a tablet diverter (5) which diverts the tablets to a recycle stream, reject stream or one of two bottle filling positions based upon instruction from the inspection. A bottle conveyor system (7) is provided which feeds empty bottles into a bottle escapement mechanism (75) which positions the empty bottles for filling. Filled bottles are moved from the bottle escapement mechanism (75) to an exit conveyor (79). The entire system is computer controlled by various control mechanisms to enable the system to be fully operational without operator assistance.

公开(公告)号：EP1248618A1

公开(公告)日：2002-10-16

申请号：EP00980817.1

申请日：2000-11-27

申请人： MERCK FROSST CANADA INC. ,  MERCK & CO., INC.

发明人： CLAS, Sophie, Dorothee ,  O'SHEA, Paul ,  DALTON, Chad ,  CROCKER, Louis, S. ,  MCCAULEY, James, A. ,  TILLYER, Richard, D. ,  DAVIES, Ian

IPC分类号： A61K31/44 ,  C07D213/22

CPC分类号： A61K31/444 ,  C07D213/61

摘要： Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase -2 (COX-2) inhibitor.

公开(公告)号：EP1244444A1

公开(公告)日：2002-10-02

申请号：EP00974020.0

申请日：2000-10-27

申请人： Merck & Co., Inc.

发明人： AL-DEHNEH, Anthony ,  HUNKE, William, A. ,  ILLIG, Kathleen, J. ,  KANIKE, Anand ,  PATEL, Hiren ,  REYNOLDS, Scott, D. ,  TSINONTIDES, Stelios, C.

IPC分类号： A61K31/407 ,  A61P31/04 ,  C07D487/04

CPC分类号： C07D477/20 ,  A61K31/407 ,  C07D477/02

摘要： A novel process for preparing a stabilized, lyophilized carbapenem, antibiotic formulation suitable for intravenous administration to patients in need thereof, wherein the active ingredient is of formula (II). The process entails compounding an unstable, monosodium salt carbapenem with a sodium bicarbonate solution at a temperature range of from about 0° to about 5°C while maintaining a pH between about 7.0 and about 8.0, filtering the resultant solution, bottling under sterile conditions, and lyophilizing to produce the formulation.

公开(公告)号：EP0759757B1

公开(公告)日：2002-08-21

申请号：EP95924570.5

申请日：1995-05-12

申请人： MERCK & CO., INC.

发明人： BRENNER, Gerald, S. ,  KATDARE, Ashok, V. ,  PRETZER, Denise ,  WHITEFORD, Donna, T.

IPC分类号： A61K31/66 ,  A61K9/00 ,  A61K47/12 ,  A61P19/08

CPC分类号： A61K9/0095 ,  A61K31/663

摘要： Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.

公开(公告)号：EP1227722A1

公开(公告)日：2002-08-07

申请号：EP00975482.1

申请日：2000-10-27

申请人： Merck & Co., Inc.

发明人： BALKOVEC, James, M. ,  HAMMOND, Gail ,  GREENLEE, Mark, L. ,  OLSON, Steven, H. ,  ROUEN, Gregory, P. ,  EPSTEIN-TONEY, Jeffrey, H.

IPC分类号： A01N37/00 ,  A01N37/10 ,  A01N37/30 ,  A01N37/44 ,  A01N43/02 ,  A01N43/16 ,  A01N43/64 ,  A01N57/00 ,  C07C63/313 ,  C07C57/34 ,  C07D211/70 ,  C07D239/02 ,  C07D307/02

CPC分类号： C07D307/91 ,  C07C57/34 ,  C07C57/38 ,  C07C57/40 ,  C07C57/46 ,  C07C57/48 ,  C07C57/58 ,  C07C59/48 ,  C07C59/52 ,  C07C59/64 ,  C07C59/68 ,  C07D209/86 ,  C07D213/55 ,  C07D307/54 ,  C07D317/60 ,  C07D333/24 ,  C07D333/76

摘要： This invention relates to novel substituted succinic acid metallo-β-lactamase inhibitors which are useful potentiators of β-lactam antibiotics. Accordingly, the present invention provides a method of treating bacterial infections in animals or humans which comprises administering, together with a β-lactam antibiotic, a therapeutically effective amount of a compound of formula (I) including pharmaceutically acceptable salts, prodrugs, anhydrides, and solvates thereof.

公开(公告)号：EP1227721A1

公开(公告)日：2002-08-07

申请号：EP00975454.0

申请日：2000-10-27

申请人： Merck & Co., Inc.

发明人： BALKOVEC, James, M. ,  GREENLEE, Mark, L. ,  OLSON, Steven, H. ,  ROUEN, Gregory, P.

IPC分类号： A01N37/00 ,  A01N37/10 ,  A01N37/30 ,  A01N37/44 ,  A01N43/02 ,  A01N43/16 ,  A01N43/64 ,  A01N57/00 ,  C07C63/313 ,  C07C57/34 ,  C07D211/70 ,  C07D239/02 ,  C07D307/02

CPC分类号： C07D307/91 ,  C07C57/38 ,  C07C57/58 ,  C07C59/64 ,  C07C69/612 ,  C07C69/734 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D333/20 ,  C07D405/06 ,  C07D409/06

摘要： This invention relates to novel substituted succinic acid metallo-β-lactamase inhibitors which are useful potentiators of β-lactam antibiotics. Accordingly, the present invention provides a method of treating bacterial infections in animals or humans which comprises administering, together with a b-lactam antibiotic, a therapeutically effective amount of a compound of formula (I), including pharmaceutically acceptable salts, prodrugs, anhydrides, and solvates thereof.

摘要翻译： 本发明涉及新的取代的琥珀酸金属-β-内酰胺酶抑制剂，它们是β-内酰胺抗生素的有用增效剂。 因此，本发明提供了治疗动物或人的细菌感染的方法，其包括与β-内酰胺抗生素一起施用治疗有效量的式（I）化合物，包括药学上可接受的盐，前药，酸酐， 和它们的溶剂化物。

公开(公告)号：EP1206477A1

公开(公告)日：2002-05-22

申请号：EP00950713.8

申请日：2000-07-26

申请人： Merck & Co., Inc.

发明人： MACNEIL, Douglas, J. ,  OCCI, James ,  GEWAIN, Keith, M.

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N9/00 ,  C12N15/00 ,  C12N5/00 ,  C12N1/20

CPC分类号： C12N15/52

摘要： A cluster of genes involved in the synthesis and/or addition of oleandrose to avermectin aglycones has been cloned. A 11-kb PstI clone complemented 28 avermectin glycosylation mutants in seven complementation classes. Sequencing of an 10-kb region identified 9 ORFs and an additional partial ORF. Eight of the ORFs were correlated to the seven glycosylation complementation classes. Sequence comparison to Genbank databases identified 6 genes: dTDP-glucose synthase; dTDP-glucose 4,6 dehydrase; dTDP-4-keto-hexose reductase; dTDP-hexose 3,5 epimerase; dTDP-hexose 3' O-methylase; and an avermectin aglycone-dTDP-oleandrose glycosyltransferase. The ninth ORF was essential for biosynthesis of the avermectin aglycones. The partial ORF encoded part of an avermectin polyketide synthase module 7.

公开(公告)号：EP1206189A1

公开(公告)日：2002-05-22

申请号：EP00955357.9

申请日：2000-08-03

申请人： Merck & Co., Inc.

发明人： BURKE, Carl, J. ,  VOLKIN, David, B.

IPC分类号： A01N63/00

CPC分类号： A61K39/15 ,  A61K39/12 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/542 ,  C12N2720/12334

摘要： The present invention provides novel liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.

公开(公告)号：EP1200083A1

公开(公告)日：2002-05-02

申请号：EP00942778.2

申请日：2000-06-13

申请人： Merck & Co., Inc.

发明人： BERNARD-KING, Aurora, M. ,  HIRSCH, Charles, F. ,  SALVATORE, Michael, J., Jr. ,  SIGMUND, Janet, M. ,  TSIPOURAS, Athanasios ,  WILSON, Kenneth, E.

IPC分类号： A61K31/40 ,  C07D207/20 ,  C12N1/20

CPC分类号： C12P17/10 ,  C07D207/28

摘要： Fermentation of a nutrient medium with a eubacterium pseudomonas sp. yields a novel broad spectrum antibiotic compound of structure(I).

摘要翻译： 用假单胞菌属假单胞菌（Pseudomonas sp。）发酵营养培养基。 产生结构（I）的新型广谱抗生素化合物。

公开(公告)号：EP0910375B1

公开(公告)日：2002-05-02

申请号：EP97932188.2

申请日：1997-06-20

申请人： MERCK & CO., INC.

发明人： CHEN, Tzyy-Show, H. ,  GROSSMAN, William ,  ISKANDARANI, Bassel ,  KRAMER, Kenneth, A. ,  SWEET, Charles, S.

IPC分类号： A61K31/40 ,  A61K31/41 ,  A61K31/415

CPC分类号： A61K9/4808 ,  A61K9/209 ,  A61K38/556 ,  A61K31/415 ,  A61K2300/00

摘要： The present invention also relates to a pharmaceutical composition of enalapril and losartan and a pharmaceutically acceptable carrier. The present invention also relates to a method of treating hypertension and heart failure with the coadministration of enalapril and losartan.